PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q2 2026, worth $45.9M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding PMV Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 120 | 2 | 115 | −3 |
| Shares | 58.2M | 370 | 54.5M | −3.63M (−6.2%) |
| Value | $692.3M | $5.00K | $474.5M | −$217.8M (−31.5%) |
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Connor, Clark & Lunn Investment Management Ltd. | 115,689 | $1.01M | 0.01% |
| Balyasny Asset Management LLC | 34,147 | $297.1K | 0.00% |
| Dynamic Technology Lab Private Ltd | 24,869 | $216.0K | 0.02% |
| Ergoteles LLC | 23,358 | $203.2K | 0.01% |
| D. E. Shaw & Co., Inc. | 15,967 | $138.9K | 0.00% |
| Landscape Capital Management, L.L.C. | 11,191 | $97.4K | 0.01% |
| Bridgefront Capital, LLC | 11,180 | $97.3K | 0.07% |
| Point72 Middle East FZE | 8,266 | $71.9K | 0.01% |
| Quantbot Technologies LP | 5,706 | $49.6K | 0.00% |
| Group One Trading, L.P. | 3,682 | $32.0K | 0.00% |
| Aquatic Capital Management LLC | 2,300 | $20.0K | 0.00% |
| Simplex Trading, LLC | 982 | $8.00K | 0.00% |
| Rockefeller Capital Management L.P. | 220 | $1.00K | 0.00% |
Sold out (16)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Ra Capital Management, L.P. | 1,710,265 | $20.4M |
| Tudor Investment Corp Et Al | 85,553 | $1.02M |
| Victory Capital Management Inc | 49,330 | $587.0K |
| Ensign Peak Advisors, Inc | 34,718 | $413.0K |
| Jump Financial, LLC | 29,676 | $353.0K |
| Graham Capital Management, L.P. | 28,189 | $335.0K |
| Alps Advisors Inc | 24,898 | $296.0K |
| HighVista Strategies LLC | 23,324 | $278.0K |
| Schonfeld Strategic Advisors LLC | 22,275 | $265.0K |
| XTX Topco Ltd | 19,134 | $228.0K |
| Bayesian Capital Management, LP | 18,200 | $217.0K |
| Point72 Hong Kong Ltd | 9,512 | $113.0K |
| Wells Fargo & Company | 1,888 | $23.0K |
| Quadrant Capital Group LLC | 179 | $2.00K |
| Howe & Rusling Inc | 72 | $1.00K |
| Parallel Advisors, LLC | 11 | $0 |
Not filed for Q4 2022 yet (2)
Institutions that held PMV Pharmaceuticals, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Wipfli Financial Advisors LLC, | 318 | $4.00K |
| FourThought Financial, LLC | 52 | $1.00K |